Clinical Trial Update: Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial assessing safety and tolerability of the allogeneic tumor vaccine BIWB 2 in patients with advanced malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BIWB 2

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Melanoma | Phase 1 | Status: COMPLETED